A cross‐national cost‐effectiveness analysis of brivaracetam focusing on psychiatric and behavioral adverse effects
BRV causes fewer PBAEs than LEV, but costs more, creating a clinical dilemma. A cost-effectiveness analysis comparing BRV versus LEV as initial monotherapy with a focus on PBAEs was conducted across the US, Australia, and Japan. The results indicated that compared with LEV, BRV is cost-effective in Australia, but not in the US. In Japan, BRV is cost-effective as initial treatment only for patients at high risk for LEV-induced PBAEs.
Authors
- Takuji Nishida (ORCID: https://orcid.org/0000-0001-5391-4656)
- Yasushi Maruyama (ORCID: https://orcid.org/0009-0005-5734-0166)
- Kohei Ninomiya (ORCID: https://orcid.org/0000-0001-6232-0008)
- Shiori Ogawa (ORCID: https://orcid.org/0009-0002-5669-9263)
- Masashi Ikeda (ORCID: https://orcid.org/0000-0001-6237-2449)
- Hiroki Kimura (ORCID: https://orcid.org/0000-0001-9419-9855)
Institutions
- Fujita Health University (JP)
- National Epilepsy Center (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1002/epi4.70142
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00